Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
The historical rank and industry rank for Beximco Pharmaceuticals's Beneish M-Score or its related term are showing as below:
During the past 13 years, the highest Beneish M-Score of Beximco Pharmaceuticals was -1.48. The lowest was -2.83. And the median was -2.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:BXPHARMA vs ZTS, UTHR, VTRS: Beneish M-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Beximco Pharmaceuticals for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 *
+
0.528 *
+
0.404 *
+
0.892 *
+
0.115 *
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 *
+
4.679 *
-
0.327 *
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(1160.954 / (1160.954 + 0))
/
(1341.623 / (1341.623 + 45246.003))
=
1
/
0.028798
=
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(8649.567 - 0
-
4978.701)
/
78731.251
=
0.046625
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Beximco Pharmaceuticals (DHA:BXPHARMA) has a Beneish M-Score of 0.00 as of Aug. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beximco Pharmaceuticals and its competitors. According to the industry distribution chart, Beximco Pharmaceuticals ranks #999999 out of 912 companies in the Drug Manufacturers industry.
Is Beximco Pharmaceuticals' Beneish M-Score too high?
Beximco Pharmaceuticals' current Beneish M-Score is 0.00. Based on the distribution chart, Beximco Pharmaceuticals ranks #999999 out of 912 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #999999 out of 912 companies for Beneish M-Score. This places Beximco Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (DHA:BXPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT128.18, compared to a current price of BDT150.90 — trading 17.7% above its estimated fair value. The current Beneish M-Score is 0.00. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Beximco Pharmaceuticals (DHA:BXPHARMA), the current Beneish M-Score is 0.00 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beximco Pharmaceuticals (DHA:BXPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued.
The current stock price of BDT150.90 is trading 17.7% above its estimated GF Value™ of BDT128.18.
GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for DHA:BXPHARMA:
Beneish M-Score: 0.00
GF Value™: BDT128.18 vs. price of BDT150.90 (17.7% above fair value)
No single metric tells the full story. See the DHA:BXPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
94GF Score
Get the complete analysis for DHA:BXPHARMA
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:BXPHARMA has been successfully added to your 
